全文获取类型
收费全文 | 1318篇 |
免费 | 95篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 61篇 |
妇产科学 | 6篇 |
基础医学 | 242篇 |
口腔科学 | 8篇 |
临床医学 | 87篇 |
内科学 | 249篇 |
皮肤病学 | 7篇 |
神经病学 | 211篇 |
特种医学 | 46篇 |
外科学 | 44篇 |
综合类 | 110篇 |
预防医学 | 55篇 |
眼科学 | 11篇 |
药学 | 226篇 |
中国医学 | 60篇 |
肿瘤学 | 34篇 |
出版年
2023年 | 10篇 |
2022年 | 14篇 |
2021年 | 28篇 |
2020年 | 34篇 |
2019年 | 24篇 |
2018年 | 33篇 |
2017年 | 33篇 |
2016年 | 41篇 |
2015年 | 47篇 |
2014年 | 74篇 |
2013年 | 88篇 |
2012年 | 67篇 |
2011年 | 79篇 |
2010年 | 94篇 |
2009年 | 71篇 |
2008年 | 47篇 |
2007年 | 59篇 |
2006年 | 54篇 |
2005年 | 53篇 |
2004年 | 28篇 |
2003年 | 40篇 |
2002年 | 31篇 |
2001年 | 32篇 |
2000年 | 22篇 |
1999年 | 14篇 |
1998年 | 19篇 |
1997年 | 14篇 |
1996年 | 23篇 |
1995年 | 13篇 |
1994年 | 20篇 |
1993年 | 25篇 |
1992年 | 21篇 |
1991年 | 18篇 |
1990年 | 15篇 |
1989年 | 9篇 |
1988年 | 13篇 |
1987年 | 12篇 |
1986年 | 7篇 |
1985年 | 15篇 |
1984年 | 15篇 |
1983年 | 8篇 |
1982年 | 9篇 |
1981年 | 10篇 |
1980年 | 11篇 |
1979年 | 6篇 |
1977年 | 6篇 |
1976年 | 11篇 |
1972年 | 6篇 |
1971年 | 5篇 |
1968年 | 9篇 |
排序方式: 共有1458条查询结果,搜索用时 156 毫秒
1.
目的探讨小檗碱调节糖原代谢的机制及对糖原结构的影响。方法采用自发型糖尿病模型db/db小鼠作为疾病模型鼠,考察小檗碱对db/db小鼠血糖水平的影响;提取小鼠的肝糖原进行体积排阻色谱(SEC)和透射电镜(TEM)分析,考察小檗碱对db/db小鼠肝糖原的结构影响,并探讨其影响机制。结果小檗碱可以显著性降低db/db小鼠的空腹血糖,降低db/db小鼠血清胰岛素水平;改善db/db小鼠肝糖原的结构不稳定性;降低db/db小鼠肝组织中糖原磷酸化酶(GP)、糖原脱分支酶(GDBE)和环磷酸腺苷(cAMP)表达水平,降低血清胰高血糖素水平。结论小檗碱可以调控cAMP/GP信号通路,改善db/db小鼠的肝糖原结构,修复受损糖原结构,这可能是其调节肝糖代谢,改善糖尿病症状的机制之一。 相似文献
2.
3.
Yi-Ju Hsu Wei-Lun Jhang Mon-Chien Lee Batsuren Bat-Otgon Erdenechuluun Narantungalag Chi-Chang Huang 《International journal of medical sciences》2021,18(2):564
Fatigue may cause the efficiency of the organ in human body to decrease, which may affect the daily life and exercise performance of the general people and athletes. Mare''s milk powder (MMP) is a lactose rich supplement. The research of the study is to evaluate the whether MMP has anti-fatigue effect. Forty male ICR mice were randomly divided into four group to receive vehicle or MMP by oral gavage at 0 (Vehicle), 0.27 (MMP-1X), 0.54 (MMP-2X), 1.35 (MMP-5X) g/kg/day for 14 days. The forelimb grip of the MMP-2X, and MMP-5X group were significantly higher than the vehicle group. The swim-to-exhaustion times of the MMP-1X, MMP-2X, and MMP-5X group were significantly greater than the vehicle group. Glycogen levels in liver and muscle were significantly larger in the MMP-1X, MMP-2X, and MMP-5X groups than the vehicle group. Receive MMP supplement for 14 days can promoting exercise performance and amelioration of exercise-induced fatigue. 相似文献
4.
5.
In the second part we focus on two treatment strategies that may overcome the main limitations of current antidepressant drugs. First, we review the experimental and clinical evidence supporting the use of glutamatergic drugs as fast-acting antidepressants. Secondly, we review the involvement of microRNAs (miRNAs) in the pathophysiology of major depressive disorder (MDD) and the use of small RNAs (e.g.., small interfering RNAs or siRNAs) to knockdown genes in monoaminergic and non-monoaminergic neurons and induce antidepressant-like responses in experimental animals.The development of glutamatergic agents is a promising venue for antidepressant drug development, given the antidepressant properties of the non-competitive NMDA receptor antagonist ketamine. Its unique properties appear to result from the activation of AMPA receptors by a metabolite [(2 S,6 S;2 R,6 R)-hydroxynorketamine (HNK)] and mTOR signaling. These effects increase synaptogenesis in prefrontal cortical pyramidal neurons and enhance serotonergic neurotransmission via descending inputs to the raphe nuclei. This view is supported by the cancellation of ketamine's antidepressant-like effects by inhibition of serotonin synthesis.We also review existing evidence supporting the involvement of miRNAs in MDD and the preclinical use of RNA interference (RNAi) strategies to target genes involved in antidepressant response. Many miRNAs have been associated to MDD, some of which e.g., miR-135 targets genes involved in antidepressant actions. Likewise, SSRI-conjugated siRNA evokes faster and/or more effective antidepressant-like responses. Intranasal application of sertraline-conjugated siRNAs directed to 5-HT1A receptors and SERT evoked much faster changes of pre- and postsynaptic antidepressant markers than those produced by fluoxetine. 相似文献
6.
Extension of the Pompe mutation database by linking disease‐associated variants to clinical severity
Monica Y. Nio Stijn L.M. in 't Groen Atze J. Bergsma Nadine A.M.E. van der Beek Marian Kroos Marianne Hoogeveen‐Westerveld Ans T. van der Ploeg W.W.M. Pim Pijnappel 《Human mutation》2019,40(11):1954-1967
Pompe disease is an autosomal recessive lysosomal storage disorder caused by disease‐associated variants in the acid alpha‐glucosidase (GAA) gene. The current Pompe mutation database provides a severity rating of GAA variants based on in silico predictions and expression studies. Here, we extended the database with clinical information of reported phenotypes. We added additional in silico predictions for effects on splicing and protein function and for cross reactive immunologic material (CRIM) status, minor allele frequencies, and molecular analyses. We analyzed 867 patients and 562 GAA variants. Based on their combination with a GAA null allele (i.e., complete deficiency of GAA enzyme activity), 49% of the 422 disease‐associated variants could be linked to classic infantile, childhood, or adult phenotypes. Predictions and immunoblot analyses identified 131 CRIM negative and 216 CRIM positive variants. While disease‐associated missense variants were found throughout the GAA protein, they were enriched up to seven‐fold in the catalytic site. Fifteen percent of disease‐associated missense variants were predicted to affect splicing. This should be confirmed using splicing assays. Inclusion of clinical severity rating in the Pompe mutation database provides an invaluable tool for diagnosis, prognosis of disease progression, treatment regimens, and the future development of personalized medicine for Pompe disease. 相似文献
7.
8.
9.
Stefan Wagenpfeil PhD María V Andrés PhD Vincente Belloch MD Teresa León MD PhD Teodoro del Ser MD for the TAUROS MRI Investigators 《Movement disorders》2014,29(4):479-487
It is believed that glycogen synthase kinase‐3 hyperphosphorylates tau protein in progressive supranuclear palsy (PSP). The Tau Restoration on PSP (TAUROS) trial assessed the glycogen synthase kinase‐3 inhibitor tideglusib as potential treatment. For the magnetic resonance imaging (MRI) substudy reported here, we assessed the progression of brain atrophy. TAUROS was a multinational, phase 2, double‐blind, placebo‐controlled trial in patients with mild‐to‐moderate PSP who were treated with oral tideglusib (600 mg or 800 mg daily) or with placebo for 1 year. A subset of patients underwent baseline and 52‐week MRI. Automated, observer‐independent, atlas‐based, and mask‐based volumetry was done on high‐resolution, T1‐weighted, three‐dimensional data. For primary outcomes, progression of atrophy was compared both globally (brain, cerebrum) and regionally (third ventricle, midbrain, pons) between the active and placebo groups (Bonferroni correction). For secondary outcomes, 15 additional brain structures were explored (Benjamini & Yekutieli correction). In total, MRIs from 37 patient were studied (placebo group, N = 9; tideglusib 600 mg group, N = 19; tideglusib 800 mg group, N = 9). The groups compared well in their demographic characteristics. Clinical results showed no effect of tideglusib over placebo. Progression of atrophy was significantly lower in the active group than in the placebo group for the brain (mean ± standard error of the mean: ?1.3% ± 1.4% vs. ?3.1% ± 2.3%, respectively), cerebrum (?1.3% ± 1.5% vs. ?3.2% ± 2.1%, respectively), parietal lobe (?1.6% ± 1.9% vs. ?4.1% ± 3.0%, respectively), and occipital lobe (?0.3% ± 1.8% vs. ?2.7% ± 3.2%, respectively). A trend toward reduced atrophy also was observed in the frontal lobe, hippocampus, caudate nucleus, midbrain, and brainstem. In patients with PSP, tideglusib reduced the progression of atrophy in the whole brain, particularly in the parietal and occipital lobes. © 2014 International Parkinson and Movement Disorder Society 相似文献
10.